Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 1:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 201 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Early Stage Lung Cancer Clear all
Recruiting Phase 1Phase 2 Interventional

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT06694454
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma
Interventions
azacytidine, carboplatin, paclitaxel, durvalumab, cisplatin, gemcitabine, pemetrexed
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jun 25, 2026, 1:57 PM EDT
Completed Phase 2 Interventional Results available

Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer

NCT00470054
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Interventions
dasatinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Jun 25, 2026, 1:57 PM EDT
Active, not recruiting No phase listed Observational

Using e-Nose Technology to Identify Early Lung Cancer

NCT04734145
View directory record Official record
Conditions
Lung; Node, Lung Cancer
Interventions
Breathprinting test
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 85 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 25, 2026, 1:57 PM EDT
Completed Phase 2 Interventional

Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer

NCT00308529
View directory record Official record
Conditions
Carcinoma, Small Cell Lung, Lung Cancer
Interventions
irinotecan, carboplatin, bevacizumab, Radiation Therapy
Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Fort Myers, Florida • Cincinnati, Ohio • Chattanooga, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2010 · Synced Jun 25, 2026, 1:57 PM EDT
Withdrawn Phase 2 Interventional

Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

NCT06654050
View directory record Official record
Conditions
Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma, BRCA1-Associated Protein-1 (BAP1) Mutations, Early-stage BAP1-associated Malignancies
Interventions
alrizomadlin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jun 25, 2026, 1:57 PM EDT
Completed Phase 2 Interventional

The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)

NCT00043862
View directory record Official record
Conditions
Lung Cancer, Small Cell, Small Cell Lung Cancer
Interventions
topotecan
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Jun 25, 2026, 1:57 PM EDT
Completed Phase 2 Interventional Results available

Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer

NCT00066742
View directory record Official record
Conditions
Limited Stage Small Cell Lung Cancer
Interventions
tirapazamine, cisplatin, etoposide, radiation therapy, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Jun 25, 2026, 1:57 PM EDT
Completed No phase listed Observational

Psychosocial Adjustment After Radiation Therapy in Patients With Cancer

NCT00905086
View directory record Official record
Conditions
Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
questionnaire administration, cognitive assessment, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2015 · Synced Jun 25, 2026, 1:57 PM EDT
Completed Phase 1 Interventional

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

NCT00036790
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
doxorubicin hydrochloride, motexafin gadolinium
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jun 25, 2026, 1:57 PM EDT
Completed Phase 2 Interventional Results available

G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer

NCT00554463
View directory record Official record
Conditions
Lung Cancer
Interventions
Filgrastim, Pegfilgrastim, Etoposide, Cisplatin, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
14
States / cities
Gainesville, Florida • Miami Beach, Florida • Lexington, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Jun 25, 2026, 1:57 PM EDT
Withdrawn Phase 2 Interventional

A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)

NCT01480141
View directory record Official record
Conditions
Lung Cancer
Interventions
BIBW 2992 (Afatinib)
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Jun 25, 2026, 1:57 PM EDT
Completed Not applicable Interventional

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

NCT00002520
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
nicotine, Usual Care
Drug · Behavioral
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
19 Years to 120 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jun 25, 2026, 1:57 PM EDT
Completed Phase 2 Interventional Results available

Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer

NCT00654030
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
1650-G Vaccine
Drug
Lead sponsor
Edward Hirschowitz
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Danville, Kentucky • Lexington, Kentucky • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2018 · Synced Jun 25, 2026, 1:57 PM EDT
Completed Not applicable Interventional Results available

Feasibility Study Incorporating Lung Function Imaging Into Radiation Therapy for Lung Cancer Patients

NCT02528942
View directory record Official record
Conditions
Lung Neoplasms, Lung Cancer
Interventions
Radiation therapy
Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Aurora, Colorado • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Jun 25, 2026, 1:57 PM EDT
Completed Not applicable Interventional

Early Detection of Second Lung Cancer in Patients With Stage I Non-small Cell Lung Cancer

NCT00002667
View directory record Official record
Conditions
Lung Cancer
Interventions
cytology specimen collection procedure, immunoenzyme technique, study of high risk factors
Other · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
5
States / cities
Tampa, Florida • Des Moines, Iowa • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jun 25, 2026, 1:57 PM EDT
Recruiting Not applicable Interventional

Study Comparing Two Different Schedules of Radiation for Early-stage Lung Cancer

NCT03706027
View directory record Official record
Conditions
Lung Cancer
Interventions
radiation therapy-3 fractions, Radiation therapy-5 fractions
Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Jun 25, 2026, 1:57 PM EDT
Terminated Phase 4 Interventional

Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

NCT05583188
View directory record Official record
Conditions
NSCLC
Interventions
Aliya Pulsed Electric Fields (PEF) ablation, Nivolumab plus Platinum Doublet Chemotherapy, Standard of care neoadjuvant therapy, Surgical Resection
Device · Drug · Other
Lead sponsor
Galvanize Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Jun 25, 2026, 1:57 PM EDT
Completed Not applicable Interventional

Strides for Life I: Increasing Physical Activity in Stage 1 Lung Cancer Patients

NCT02755883
View directory record Official record
Conditions
Lung Cancer
Interventions
Physical activity plus positive affect, Physical activity plus education
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 110 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Jun 25, 2026, 1:57 PM EDT
Completed Phase 1 Interventional

Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer

NCT00005022
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2010
U.S. locations
242
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 189 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2013 · Synced Jun 25, 2026, 1:57 PM EDT
Not listed Phase 2 Interventional

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer

NCT00003284
View directory record Official record
Conditions
Lung Cancer
Interventions
filgrastim, carboplatin, etoposide, ifosfamide, paclitaxel, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Jun 25, 2026, 1:57 PM EDT
Terminated Phase 1 Interventional

Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung

NCT03321747
View directory record Official record
Conditions
Lung Cancer
Interventions
Stereotactic Ablative Body Radiation (SABR)
Radiation
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jun 25, 2026, 1:57 PM EDT
Active, not recruiting Phase 1 Interventional

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

NCT05353439
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Pembrolizumab, Tazemetostat Hydrobromide, Topotecan Hydrochloride
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Los Angeles, California • Newport Beach, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 25, 2026, 1:57 PM EDT
Terminated Not applicable Interventional Results available

Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer

NCT01532362
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Apricoxib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Jun 25, 2026, 1:57 PM EDT
Terminated No phase listed Observational

Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up

NCT02121925
View directory record Official record
Conditions
Lung Cancer, NSCLC, Lung Adenocarcinoma
Interventions
Not listed
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Jun 25, 2026, 1:57 PM EDT